Level C· Early human research exploring benefitsCohort StudyPubMedOpen access

Impact of neoadjuvant chemotherapy on the functionality of adipose-derived mesenchymal stromal cells and their modulatory effects on fibroblasts in oncology patients.

Skoniecka A., Słonimska P., Tymińska A., Czerwiec K., Deptuła M., Zawrzykraj M.

Cohort Study on Chronic Wound, published in Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Sci Rep (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41688670
PMCID
PMC12976306
DOI
10.1038/s41598-026-39457-9

Abstract (original English)

Adipose-derived mesenchymal stromal cells (AD-MSCs), also known as mesenchymal stem cells, hold great promise in regenerative medicine due to their pleiotropic effects, including the secretion of cytokines, chemokines, and growth factors. These cells can promote tissue repair, enhance angiogenesis, and modulate inflammation. However, understanding neoadjuvant chemotherapy’s impacts on AD-MSC functionality, immunophenotype, cytokine secretion, and their interactions with fibroblasts remains insufficient. This study aimed to investigate the effects of chemotherapy on AD-MSCs and their ability to influence fibroblast function in vitro. Human, autologous AD-MSCs and skin fibroblasts were isolated from two patient cohorts - those without and those after neoadjuvant chemotherapy, from subcutaneous adipose tissue obtained during surgical procedures. AD-MSCs identity was confirmed by flow cytometry, positive and negative markers, and by induction of adipogenic, osteogenic, and chondrogenic differentiation. Autologous fibroblasts were co-cultured with AD-MSCs to assess fibroblast chemotaxis, proliferation, migration, cytokine secretion, cell-cycle distribution, collagen deposition, and gene expression. Flow cytometric analysis of surface markers, secreted cytokines, transcriptomic analysis, and the cell cycle revealed no significant differences between AD-MSCs from patients who either r

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMesenchymal Stem CellsFibroblastsNeoadjuvant TherapyFemaleAdipose TissueCell DifferentiationCell ProliferationCell MovementCytokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research